Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients
Dexamethasone Remains Only Proven Therapy In Severe Disease
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.
You may also be interested in...
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.